LPR-2: a prospective, single-center, non-randomized, interventional study on the effectiveness and safety of combined immunotargeted therapy in patients with metastatic non-small cell cancer with a RET gene translocation
Recruiting now
This interventional study will evaluate the effectiveness, safety, and tolerability of pembrolizumab in combination with lenvatinib in adults with metastatic non-small cell lung cancer (NSCLC) who have a confirmed RET gene rearrangement and whose disease has progressed after one …
Phase 3 • Sponsor: EuroCityClinic LLC
Last updated Sep 09, 2026 19:00 UTC